-
Deferasirox Fe3+ chelate
- names:
Deferasirox Fe3+ chelate
- CAS号:
554435-83-5
MDL Number: - MF(分子式): C21H12FeN3O4 MW(分子量): 426.18
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM004745-5mg | 5mg | >98.0% | ¥ 2970.00 | ¥ 2970.00 | 2-3天 | ¥ 0.00 | ||
| YZM004745-2mg | 2mg | >98.0% | ¥ 1302.60 | ¥ 1302.60 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | Deferasirox Fe3+ chelate |
| CAS号 | 554435-83-5 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C21H12FeN3O4 |
| 分子量 Molecular Weight | 426.18 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度50 mg/mL(117.32 mM;Need ultrasonic) |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years 4°C 2 years / In solvent溶液中: -80°C 6 months月 -20°C 1 month月 |
| 产品说明 | |
| Introduction | Deferasirox Fe3+ chelate is a rationallyesigned oral iron chelator; its main use is to reduce chronic iron overload in patients who are receiving longerm blood transfusions for conditions such as betahalassemia and other chronic anemias. |
| Application1 | |
| Application2 | |
| Application3 |
Deferasirox Fe3+ chelate is a rationally-designed oral iron chelator; its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.
【1】.Yang LP, Keam SJ, Keating GM. Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
【2】.Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010 Jul;9(4):633-41.
【3】.Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):123-34.
【4】.Donnelly JP, Lahav M. Deferasirox as adjunctive therapy for mucormycosis. J Antimicrob Chemother. 2012 Mar;67(3):519-20.
【5】.Lui GY, Obeidy P, Ford SJ et al. The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Mol Pharmacol. 2012 Oct 16. [Epub ahead of print]
【2】.Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010 Jul;9(4):633-41.
【3】.Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):123-34.
【4】.Donnelly JP, Lahav M. Deferasirox as adjunctive therapy for mucormycosis. J Antimicrob Chemother. 2012 Mar;67(3):519-20.
【5】.Lui GY, Obeidy P, Ford SJ et al. The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Mol Pharmacol. 2012 Oct 16. [Epub ahead of print]
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


